IDEXX Laboratories (NASDAQ:IDXX) Posts Earnings Results, Beats Estimates By $0.15 EPS

IDEXX Laboratories (NASDAQ:IDXX) announced its earnings results on Monday. The company reported $3.08 EPS for the quarter, topping the consensus estimate of $2.93 by $0.15, Briefing.com reports. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.53 earnings per share. IDEXX Laboratories updated its FY 2026 guidance to 14.290-14.800 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• IDEXX delivered strong results with Q4 revenue up 14% reported / 12% organic, full‑year organic revenue +10%, Q4 EPS of $3.08 (+17% comparable) and record premium instrument placements including nearly 6,400 inVue Dx and a ~78,000 Catalyst install base.
• Management provided 2026 guidance of $4.632B–$4.72B in revenue (≈7%–9% organic), targeted 8%–10% organic growth in CAG Diagnostics recurring revenue, and EPS of $14.29–$14.80 (≈10%–14% comparable growth).
• Demand headwinds persist as U.S. same‑store clinical visits remain down (≈-1.7% Q4, -1.9% FY2025), company plans for ≈-2% visit declines in 2026, and Rapid Assay revenue fell ~3% in Q4 partly from transitioning pancreatic lipase to Catalyst (≈4% headwind).
• Innovation momentum is a key growth driver — inVue Dx contributed >$75M of instrument revenue in 2025 with a planned ~5,500 placements in 2026, Cancer Dx will add mast cell tumor detection mid‑2026, and Catalyst menu expansions plus software (Vello, cloud PIMS) are lifting consumables and utilization.
• Financial flexibility remains strong with 2025 free cash flow of $1.1B (100% of net income), $1.2B of share repurchases (2.4M shares), low leverage (~0.5x gross), and 2026 guidance for ~85%–95% net income‑to‑FCF conversion with capex of ~$180M.

IDEXX Laboratories Trading Down 4.6%

NASDAQ IDXX opened at $639.60 on Tuesday. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. IDEXX Laboratories has a 1-year low of $356.14 and a 1-year high of $769.98. The firm’s fifty day simple moving average is $703.10 and its 200-day simple moving average is $662.65. The company has a market capitalization of $51.07 billion, a PE ratio of 50.72, a price-to-earnings-growth ratio of 3.58 and a beta of 1.67.

IDEXX Laboratories News Roundup

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q4 results beat expectations — EPS $3.08 vs. $2.93 estimate and revenue $1.091B vs. $1.07B estimate; revenue rose ~14% YoY and margins expanded, underscoring solid near-term profitability. IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Companion Animal Group (CAG) remains the primary growth engine — reported CAG growth of ~15% (13% organic); company cites innovation driving 8%–10% CAG diagnostics growth going forward. Idexx targets $4.632B–$4.720B revenue for 2026 as innovation drives 8%–10% CAG diagnostics growth
• Neutral Sentiment: FY‑2026 guidance: revenue $4.632B–$4.720B and EPS $14.29–$14.80 (company noted resilient vet demand and higher tests-per-visit). The range is roughly in line with, but not meaningfully above, consensus — a mixed data point for future growth modeling. IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics
• Neutral Sentiment: Full earnings call/transcript and slide deck are available for detail (useful for modeling margin trajectory, regional dynamics and product-cycle assumptions). IDEXX Laboratories, Inc. (IDXX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market reaction was negative — shares dipped despite the beat as investors parsed guidance that some viewed as conservative relative to recent momentum; pre-market selling cited in coverage. IDEXX Laboratories tops revenue forecasts, shares edge lower on outlook
• Negative Sentiment: Valuation and near‑term expectations could constrain upside — the stock trades at a rich multiple, so any guidance shortfall or slowing clinic-visit trends may pressure the stock. IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on IDXX shares. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. BTIG Research set a $800.00 target price on IDEXX Laboratories in a report on Tuesday. UBS Group boosted their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $760.50.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.98% of the stock is owned by company insiders.

Hedge Funds Weigh In On IDEXX Laboratories

Several hedge funds have recently bought and sold shares of the business. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $26,000. Caitong International Asset Management Co. Ltd bought a new stake in IDEXX Laboratories during the third quarter worth approximately $36,000. WealthCollab LLC acquired a new position in IDEXX Laboratories during the second quarter valued at approximately $30,000. Johnson Financial Group Inc. grew its holdings in IDEXX Laboratories by 1,475.0% during the third quarter. Johnson Financial Group Inc. now owns 63 shares of the company’s stock valued at $40,000 after purchasing an additional 59 shares during the last quarter. Finally, Pin Oak Investment Advisors Inc. bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $60,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.